Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Policy / Regulatory

NMPA Updates 2025 Edition of Medical Narcotic and Psychotropic Substances Catalogs

Fineline Cube Jul 28, 2025

On July 28, 2025, China’s National Medical Products Administration (NMPA), the Ministry of Public Security,...

Company Deals

Tibet Aim Pharm’s Major Shareholder Transfers Stake to Beijing Fuhao

Fineline Cube Jul 28, 2025

China-based Tibet Aim Pharm, Inc. (SHE: 002826) announced that its controlling shareholder and actual controller,...

Company Drug

Roche’s Elevidys Receives Negative CHMP Opinion for Duchenne Muscular Dystrophy

Fineline Cube Jul 28, 2025

Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced today that the Committee for Medicinal...

Company Drug

Aidea Pharma’s Aitribond Approved by Zanzibar Food and Drug Agency

Fineline Cube Jul 28, 2025

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced that its anti-HIV-1 drug Aitribond has...

Company Deals

Mirxes and NAGAWA Launch Free Gastric Cancer Screening Project in Japan

Fineline Cube Jul 28, 2025

Singapore-based Mirxes Group (HKG: 2629) announced on July 23, 2025, that it has entered into...

Company Drug

Ascletis Pharma Doses First Patients in U.S. Phase 2a Trial for Monthly GLP-1 Agonist ASC30

Fineline Cube Jul 28, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced that the first participants with obesity or overweight...

Company Drug

Sobi North America’s Doptelet Approved by FDA for Pediatric ITP Treatment

Fineline Cube Jul 28, 2025

Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi), announced today...

Company Deals

Hengrui and GSK Enter Global Licensing Pact for PDE3/4 Inhibitor HRS-9821

Fineline Cube Jul 28, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced on July 28, 2025, that it...

Company Drug

Pfizer and BioNTech’s LP.8.1 COVID-19 Vaccine Gets EMA CHMP Nod

Fineline Cube Jul 28, 2025

US giant Pfizer Inc., (NYSE: PFE) and Germany-based BioNTech SE (NASDAQ: BNTX) announced today that...

Company Medical Device

Sansure Biotech’s Gene Polymorphism Detection Kits Receive NMPA Class III IVD Certification

Fineline Cube Jul 28, 2025

China-based Sansure Biotech Inc. (SHA: 688289) announced on July 28, 2025, that it has received...

Policy / Regulatory

NMPA Approves Ambroxol Hydrochloride Oral Drops for Over-the-Counter Sale

Fineline Cube Jul 28, 2025

China’s National Medical Products Administration (NMPA) has approved the switch of ambroxol hydrochloride oral drops...

Company Drug

Biogen’s Zurzuvae Receives Positive CHMP Opinion for Postpartum Depression Treatment

Fineline Cube Jul 28, 2025

US-based Biogen (NASDAQ: BIIB) announced that the Committee for Medicinal Products for Human Use (CHMP)...

Others

GSK’s Blenrep Approved in EU for Relapsed or Refractory Multiple Myeloma

Fineline Cube Jul 28, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced today that Blenrep has received European Union (EU) approval...

Company Drug

Sanofi’s Sarclisa Approved in EU for Newly Diagnosed Multiple Myeloma

Fineline Cube Jul 28, 2025

France-based Sanofi (NASDAQ: SNY) announced that the European Commission has approved its anti-CD38 monoclonal antibody...

Company Deals

Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials

Fineline Cube Jul 28, 2025

Velavigo, a Shanghai-based pharmaceutical startup, has reportedly secured USD 60 million in a Pre-A+ financing...

Company Deals

Matchpoint Therapeutics Partners with Novartis to Develop Oral Covalent Inhibitors for Inflammatory Diseases

Fineline Cube Jul 28, 2025

Matchpoint Therapeutics, a privately held biotechnology company based in Watertown, Massachusetts, announced an exclusive option...

Company Drug

SinoCellTech’s SCT640C Injection Receives NMPA Approval for RA Clinical Trials

Fineline Cube Jul 25, 2025

China-based SinoCellTech Group Ltd (SHA: 688520) announced today that its self-developed product, SCT640C injection, has...

Company Drug

Hengrui Pharmaceuticals’ HRS8179 and HRS-1893 Receive NMPA Clinical Trial Approval

Fineline Cube Jul 25, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced today that it has received clinical...

Company Medical Device

Cryofocus Medtech’s Asthma Cryoablation System Granted FDA Breakthrough Device Designation

Fineline Cube Jul 25, 2025

China-based Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922) announced today that its self-developed asthma cryoablation...

Company Deals

3Sbio and Pfizer Finalize Licensing Agreement for PD-1/VEGF Bispecific Antibody SSGJ-707

Fineline Cube Jul 25, 2025

China-based 3Sbio Inc. (HKG: 1530) announced today that its global licensing agreement with Pfizer Inc.,...

Posts pagination

1 … 145 146 147 … 688

Recent updates

  • METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company
  • Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China
  • Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline
  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.